Cart
sales@molnova.com
ESI-09
CAS No. 263707-16-0
ESI-09( ESI09 | ESI 09 | ESI-09 )
Catalog No. M13808 CAS No. 263707-16-0
ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 32 | In Stock |
|
| 5MG | 50 | In Stock |
|
| 10MG | 80 | In Stock |
|
| 25MG | 159 | In Stock |
|
| 50MG | 288 | In Stock |
|
| 100MG | 434 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameESI-09
-
NoteResearch use only, not for human use.
-
Brief DescriptionESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively.
-
DescriptionESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively, >100-fold selectivity over PKA.
-
In Vitro——
-
In Vivo——
-
SynonymsESI09 | ESI 09 | ESI-09
-
PathwayGPCR/G Protein
-
TargetcAMP
-
RecptorEPAC1| EPAC2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number263707-16-0
-
Formula Weight330.77
-
Molecular FormulaC16H15ClN4O2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 20 mg/mL warmed (60.46 mM); DMSO: 66 mg/mL (199.53 mM)
-
SMILESN#C/C(C(C1=NOC(C(C)(C)C)=C1)=O)=N\NC2=CC=CC(Cl)=C2
-
Chemical Name(E)-2-(5-(tert-butyl)isoxazol-3-yl)-N'-(3-chlorophenyl)-2-oxoacetohydrazonoyl cyanide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Almahariq M , et al. Mol Pharmacol. 2013, 83(1), 122-128.
2. Gong B, et al. Proc natl Acad Sci U S A. 2013, 110(48), 19615-19620.
molnova catalog
related products
-
I942
I942 is a novel, selective ACyclic nucleotide (NCN) EPAC1 agonist that activates exchange proteins to regulate inflammatory gene expression in human umbilical blood tubes and inhibit pro-inflammatory cytokine signaling associated with cardiovascular disease.
-
Flumatinib
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
-
ESI-05
ESI-05 is a specific EPAC2 (exchange protein directly activated by cAMP 2) antagonist (IC50: 0.4 μM). ESI-05 inhibits cAMP-mediated activation of EPAC2, as well as EAPC2, mediated Rap1 activation.
